Morgan Stanley Maintains Equal-Weight on Mirati Therapeutics, Lowers Price Target to $42
Portfolio Pulse from Benzinga Newsdesk
Morgan Stanley analyst Michael Ulz has maintained an Equal-Weight rating on Mirati Therapeutics (NASDAQ:MRTX) and lowered the price target from $51 to $42.
July 14, 2023 | 3:06 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Morgan Stanley has maintained an Equal-Weight rating on Mirati Therapeutics and lowered the price target from $51 to $42.
The lowering of the price target by Morgan Stanley indicates a potential decrease in the stock's value. This could lead to a negative short-term impact on the stock's price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100